Background and Aim: In this study, it was aimed to examine the cytotoxic effect of temozolomide (TMZ) treatment, on MCF-7 and SKBR3 cell lines, to study the methylation levels of MGMT gene expression and gene promoter region. Methods: The MTT test was performed to determine the effective dose of TMZ. The time-dependent cell survival test was performed after the IC 50 value was found. Western blotting was performed to determine MGMT gene expression levels. High Resolution Melting (HRM) technique was used to determine the methylation levels of MGMT gene promoter region. Results: TMZ has been shown to have a high cytotoxic effect on SKBR3 cell line and low cytotoxicity on MCF-7. When MGMT expression levels before and after TMZ treatment were observed by western blotting, the gene expression levels of TMZ treatment were shown to decrease in both cell lines. It was observed that MGMT gene promoter region was hypermethylated in two cell lines, and that the application of TMZ further increase d the methylation levels in the promoter region. Conclusions: It was seen that TMZ c ould be used as a single agent in SKBR-3 cell line. With this study on breast cancer, it is expected that temozolomide treatment will lead future in vitro and in vivo studies for breast cancer.
Siegel, R.L., Miller, K.D. and Jemal, A. (2017). Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
Schüler-Toprak, S., Treeck, O. and Ortmann, O. (2017) Human Chorionic Gonadotropin and Breast Cancer. International Journal of Molecular Sciences, 18, 1587. https://doi.org/10.3390/ijms18071587
Gradishar, W.J. (2012) Taxanes for the Treatment of Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 6, 159-171. https://doi.org/10.4137/BCBCR.S8205
Kacak, S., Celik, L., Ozbas, S., Dizbay, S.S., Tükün, A. and Yalcin, B. (2011) Risk Factors in Breast Cancer, Risk Assessment and Prevention: Istanbul Consensus Meeting Report. European Journal of Breast Health, 7, 47-67.
Lim, D.H.K. and Maher, E.R. (2010) DNA Methylation: A Form of Epigenetic Control of Gene Expression. The Obstetrician & Gynaecologist, 12, 37-42. https://doi.org/10.1576/toag.12.1.037.27556
Wu, Y., Sarkissyan, M. and Vadgama, J.V. (2014) Epigenetics in Breast and Prostate Cancer. In: Verma, M., Ed., Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis, Springer, New York, 425-466. https://doi.org/10.1007/978-1-4939-1804-1_23
Eroglu, O., Baysak, M.E., Aras, B.D., Cilingir, O. and Artan, S. (2018) Detection of Promoter Hypermethylation of GSTP1 and CDH1 Genes and the Relationship of Histopathological Parameters of the Breast. ABCR, 7, 91-106. https://doi.org/10.4236/abcr.2018.72006
Li, F. and Yang, Z. (2016) O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation and Lung Cancer Risk: A Meta-Analysis. Journal of Cancer Research and Therapeutics, 12, 233. https://doi.org/10.4103/0973-1482.200745
Bozkurt, E., Atmaca, H. and Uzunoglu, S. (2013) Multiple Drug Resistance in Glioblastoma. Genel Tip Derg., 23, 133-143.
Dullea, A. and Marignol, L. (2016) MGMT Testing Allows for Personalised Therapy in the Temozolomide Era. Tumor Biology, 37, 87-96. https://doi.org/10.1007/s13277-015-4240-2
Ralhan, R. and Kaur, J. (2007) Alkylating Agents and Cancer Therapy. Expert Opinion on Therapeutic Patents, 17, 1061-1075. https://doi.org/10.1517/13543776.17.9.1061
Hegi, M.E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M. and Stupp, R. (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. The New England Journal of Medicine, 352, 997-1003. https://doi.org/10.1056/NEJMoa043331
Eroglu, C., Soyuer, S., Yildiz, O.G., Ozkan, M. and Menku, A. (2008) The Effect of Temozolomide as Consolidation Chemotherapy on Treatment Results of Glioblastoma Multiforme Patients Treated with Concomittant Radiotherapy and Temozolomide. UHOD, 18, 65-73.
Stupp, R., Mason, W.P. and van den Bent, M.J. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. Oncology Times, 27, 15-16. https://doi.org/10.1097/01.COT.0000289242.47980.f9
Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M. and Melguizo, C. (2015) Temozolomide resistance in glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS ONE, 10, e0140131. https://doi.org/10.1371/journal.pone.0140131
Patel, S.P., Kim, D.W., Bassett, R.L., Cain, S., Washington, E., Hwu, W., Bedikian, A.Y., et al. (2017) A Phase II Study of Ipilimumab plus Temozolomide in Patients with Metastatic Melanoma. Cancer Immunology, Immunotherapy, 66, 1359-1366. https://doi.org/10.1007/s00262-017-2030-y
Bobustuc, G.C., Kassam, A.B., Rovin, R.A., Jeudy, S., Smith, J.S., Isley, B., Konduri, S.D., et al. (2018) MGMT Inhibition in ER Positive Breast Cancer Leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin Inhibition and Enhances Response to Temozolomide. Oncotarget, 9, 29727-29742. https://doi.org/10.18632/oncotarget.25696
Thon, N., Kreth, S. and Kreth, F.W. (2013) Personalized Treatment Strategies in Glioblastoma: MGMT Promoter Methylation Status. OncoTargets and Therapy, 6, 1363-1372. https://doi.org/10.2147/OTT.S50208
Kitange, G.J., Carlson, B.L., Schroeder, M.A., Grogan, P.T., Lamont, J.D., Decker, P. A., Sarkaria, J.N., et al. (2009) Induction of MGMT Expression Is Associated with Temozolomide Resistance in Glioblastoma Xenografts. Neuro-Oncology, 11, 281-291. https://doi.org/10.1215/15228517-2008-090
Donson, A.M., Addo-Yobo, S.O., Handler, M.H., Gore, L. and Foreman, N.K. (2007) MGMT Promoter Methylation Correlates with Survival Benefit and Sensitivity to Temozolomide in Pediatric Glioblastoma. Pediatric Blood and Cancer, 48, 403-407. https://doi.org/10.1002/pbc.20803
Eroglu, O., Yildiz, M., Muhammedoglu, A., Kavsut, G., Güvenir, E., Muratoglu, B., et al. (2014) Association of DNA Methylation of P16INK4A (CDKN2A) and MGMT Genes and Histopathological Features of Breast Cancer. 3rd International Congress of the Molecular Biology Association of Turkey, Izmir, 10-12 September 2014, 110-141.
Fumagalli, C., Pruneri, G., Possanzini, P., Manzotti, M., Barile, M., Feroce, I., Barberis, M., et al. (2012) Methylation of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Gene in Triple-Negative Breast Cancer Patients. Breast Cancer Research and Treatment, 134, 131-137. https://doi.org/10.1007/s10549-011-1945-9
Vitellius, C., Eymerit-Morin, C., Luet, D., Fizanne, L., Foubert, F., Bertrais, S., Caroli-Bosc, F.X., et al. (2017) Relationship between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX. Clinical Drug Investigation, 37, 669-677. https://doi.org/10.1007/s40261-017-0522-3
Graziani, G., Faraoni, I., Grohmann, U., Bianchi, R., Binaglia, L., Margison, G.P., D’Atri, S., et al. (1995) O6-Alkylguanine-DNA Alkyltransferase Attenuates Triazene-Induced Cytotoxicity and Tumor Cell Immunogenicity in Murine L1210 Leukemia. Cancer Research, 55, 6231-6236.
Stupp, R., Gander, M., Leyvraz, S. and Newlands, E. (2001) Current and Future Developments in the Use of Temozolomide for the Treatment of Braintumours. Lancet Oncology, 2, 552-560. https://doi.org/10.1016/S1470-2045(01)00489-2
Parajpe, A., Bailey, N.I., Konduri, S., Bobustuc, G.C., Ali-Osman, F., Yusuf, M.A., et al. (2016) New Insights into Estrogenic Regulation of O6-Methylguanine DNA-Methyltransferase (MGMT) in Human Breast Cancer Cells: Co-Degradation of ER-α and MGMT Proteins by Fulvestrantor O6-Benzylguanine Indicates Fresh Avenues for the Rapy. Journal of Biomedical Research, 30, 393-410.
Hirose, Y., Berger, M.S., Pieper, R.O. and Cells, T.H.G. (2001) P53 Effects Both the Duration of G2/M Arrest and the Fate of p53 Effects Both the Duration of G2/M Arrest and the Fate of Temozolomide-Treated Human Glioblastoma Cells. Cancer Research, 61, 1957-1963.